vs
帕可Bio（PACB）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是帕可Bio的1.1倍（$50.3M vs $44.6M），READING INTERNATIONAL INC净利率更高（-5.1% vs -90.4%，领先85.3%），帕可Bio同比增速更快（13.8% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-19.9M），过去两年帕可Bio的营收复合增速更高（7.3% vs 5.6%）
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
PACB vs RDI — 直观对比
营收规模更大
RDI
是对方的1.1倍
$44.6M
营收增速更快
PACB
高出28.0%
-14.2%
净利率更高
RDI
高出85.3%
-90.4%
自由现金流更多
RDI
多$24.1M
$-19.9M
两年增速更快
PACB
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.6M | $50.3M |
| 净利润 | $-40.4M | $-2.6M |
| 毛利率 | 37.1% | — |
| 营业利润率 | -92.3% | -1.9% |
| 净利率 | -90.4% | -5.1% |
| 营收同比 | 13.8% | -14.2% |
| 净利润同比 | -1802.7% | -14.5% |
| 每股收益（稀释后） | $-0.11 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACBRDI
| Q4 25 | $44.6M | $50.3M | ||
| Q3 25 | $38.4M | $52.2M | ||
| Q2 25 | $39.8M | $60.4M | ||
| Q1 25 | $37.2M | $40.2M | ||
| Q4 24 | $39.2M | $58.6M | ||
| Q3 24 | $40.0M | $60.1M | ||
| Q2 24 | $36.0M | $46.8M | ||
| Q1 24 | $38.8M | $45.1M |
净利润PACBRDI
| Q4 25 | $-40.4M | $-2.6M | ||
| Q3 25 | $-38.0M | $-4.2M | ||
| Q2 25 | $-41.9M | $-2.7M | ||
| Q1 25 | $-426.1M | $-4.8M | ||
| Q4 24 | $2.4M | $-2.2M | ||
| Q3 24 | $-60.7M | $-7.0M | ||
| Q2 24 | $-173.3M | $-12.8M | ||
| Q1 24 | $-78.2M | $-13.2M |
毛利率PACBRDI
| Q4 25 | 37.1% | — | ||
| Q3 25 | 41.4% | — | ||
| Q2 25 | 36.9% | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 25.0% | — | ||
| Q2 24 | 16.5% | — | ||
| Q1 24 | 29.1% | — |
营业利润率PACBRDI
| Q4 25 | -92.3% | -1.9% | ||
| Q3 25 | -101.1% | -0.6% | ||
| Q2 25 | -112.8% | 4.8% | ||
| Q1 25 | -1154.5% | -17.2% | ||
| Q4 24 | -390.1% | 2.6% | ||
| Q3 24 | -160.3% | -0.6% | ||
| Q2 24 | -488.3% | -16.4% | ||
| Q1 24 | -209.6% | -16.7% |
净利率PACBRDI
| Q4 25 | -90.4% | -5.1% | ||
| Q3 25 | -98.9% | -8.0% | ||
| Q2 25 | -105.4% | -4.4% | ||
| Q1 25 | -1146.8% | -11.8% | ||
| Q4 24 | 6.0% | -3.8% | ||
| Q3 24 | -151.9% | -11.7% | ||
| Q2 24 | -481.3% | -27.4% | ||
| Q1 24 | -201.4% | -29.4% |
每股收益（稀释后）PACBRDI
| Q4 25 | $-0.11 | $-0.11 | ||
| Q3 25 | $-0.13 | $-0.18 | ||
| Q2 25 | $-0.14 | $-0.12 | ||
| Q1 25 | $-1.44 | $-0.21 | ||
| Q4 24 | $-0.44 | $-0.11 | ||
| Q3 24 | $-0.22 | $-0.31 | ||
| Q2 24 | $-0.64 | $-0.57 | ||
| Q1 24 | $-0.29 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $279.5M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $5.3M | $-18.2M |
| 总资产 | $784.1M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PACBRDI
| Q4 25 | $279.5M | $10.5M | ||
| Q3 25 | $298.7M | $8.1M | ||
| Q2 25 | $314.7M | $9.1M | ||
| Q1 25 | $343.1M | $5.9M | ||
| Q4 24 | $389.9M | $12.4M | ||
| Q3 24 | $471.1M | $10.1M | ||
| Q2 24 | $509.8M | $9.3M | ||
| Q1 24 | $561.9M | $7.5M |
总债务PACBRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PACBRDI
| Q4 25 | $5.3M | $-18.2M | ||
| Q3 25 | $36.1M | $-12.1M | ||
| Q2 25 | $61.5M | $-7.7M | ||
| Q1 25 | $91.6M | $-8.1M | ||
| Q4 24 | $506.6M | $-4.4M | ||
| Q3 24 | $453.1M | $1.6M | ||
| Q2 24 | $492.7M | $6.5M | ||
| Q1 24 | $649.0M | $18.0M |
总资产PACBRDI
| Q4 25 | $784.1M | $434.9M | ||
| Q3 25 | $803.2M | $435.2M | ||
| Q2 25 | $825.5M | $438.1M | ||
| Q1 25 | $860.8M | $441.0M | ||
| Q4 24 | $1.3B | $471.0M | ||
| Q3 24 | $1.5B | $495.7M | ||
| Q2 24 | $1.5B | $494.9M | ||
| Q1 24 | $1.7B | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.1M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | $4.1M |
| 自由现金流率自由现金流/营收 | -44.6% | 8.2% |
| 资本支出强度资本支出/营收 | 1.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-114.1M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流PACBRDI
| Q4 25 | $-19.1M | $4.3M | ||
| Q3 25 | $-18.7M | $295.0K | ||
| Q2 25 | $-29.4M | $1.6M | ||
| Q1 25 | $-44.1M | $-7.7M | ||
| Q4 24 | $-30.6M | $8.0M | ||
| Q3 24 | $-45.5M | $1.3M | ||
| Q2 24 | $-54.3M | $-10.4M | ||
| Q1 24 | $-75.7M | $-2.8M |
自由现金流PACBRDI
| Q4 25 | $-19.9M | $4.1M | ||
| Q3 25 | $-18.8M | $-246.0K | ||
| Q2 25 | $-29.9M | $1.2M | ||
| Q1 25 | $-45.4M | $-8.0M | ||
| Q4 24 | $-32.3M | $7.0M | ||
| Q3 24 | $-46.3M | $-1.1M | ||
| Q2 24 | $-55.7M | $-10.6M | ||
| Q1 24 | $-79.6M | $-4.7M |
自由现金流率PACBRDI
| Q4 25 | -44.6% | 8.2% | ||
| Q3 25 | -48.9% | -0.5% | ||
| Q2 25 | -75.3% | 1.9% | ||
| Q1 25 | -122.3% | -19.8% | ||
| Q4 24 | -82.3% | 12.0% | ||
| Q3 24 | -115.7% | -1.8% | ||
| Q2 24 | -154.8% | -22.7% | ||
| Q1 24 | -205.0% | -10.4% |
资本支出强度PACBRDI
| Q4 25 | 1.9% | 0.3% | ||
| Q3 25 | 0.2% | 1.0% | ||
| Q2 25 | 1.4% | 0.6% | ||
| Q1 25 | 3.7% | 0.6% | ||
| Q4 24 | 4.1% | 1.7% | ||
| Q3 24 | 2.0% | 4.0% | ||
| Q2 24 | 4.1% | 0.5% | ||
| Q1 24 | 10.0% | 4.3% |
现金转化率PACBRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -12.93× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
